Latest news about Medi Caps
Medi Caps
26.91
-0.84(-3.03%)
Company Performance:
View Company Insights1D-3.03%
1M+2.75%
6M-13.36%
1Y-37.21%
5Y-42.32%
More news about Medi Caps
13Nov 25
Medi-Caps Limited Reports Mixed Financial Performance for Q2 and H1 FY2026
Medi Caps Limited announced unaudited Q2 FY2026 results, showing a mixed performance. Consolidated revenue dropped to Rs. 268.76 crore from Rs. 829.62 crore in Q2 FY2025. However, profit before tax increased to Rs. 182.15 crore from Rs. 31.23 crore. The company's Real Estate Division generated Rs. 99.78 lakh from shop sales at Medi-caps Business Park. The pharmaceutical segment faced challenges, while real estate showed positive momentum. The company's wholly-owned subsidiary, Medgel Private Limited, reported a net loss after tax of Rs. (210.80) lakh for the quarter.
05Aug 25
Medi Caps Limited Reports Q1 Loss, Schedules AGM and Announces Board Changes
Medi Caps Limited faced substantial challenges in Q1 ending June 30. Standalone operations reported no revenue and a net loss of Rs 39.75 lakhs. Consolidated results showed a 56.61% decrease in revenue to Rs 268.76 lakhs and a widened net loss of Rs 349.19 lakhs. The Pharma Division generated Rs 268.76 lakhs in revenue but reported a segment loss of Rs 308.14 lakhs. The Real Estate Division had no revenue and a loss of Rs 39.75 lakhs. The Board scheduled the 42nd AGM for September 18, appointed Joshi Sahay and Company as Secretarial Auditor, and proposed re-appointment of Mr. Dharmendra Solanki as Independent Director.
05Aug 25
Medi-Caps Limited Re-appoints Dharmendra Solanki as Independent Director for Second Term
Medi Caps Limited has announced the re-appointment of Dharmendra Solanki as Non-Executive Independent Director for a second five-year term, from February 5, 2026, to February 4, 2031, subject to shareholder approval. Solanki, with 27 years of experience in Accounts, Finance, and Taxation, holds Commerce degrees from Vikram University. The company also approved financial results, scheduled the 42nd AGM for September 18, 2025, and appointed Joshi Sahay and Company as Secretarial Auditor for a five-year term.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,868.00
(+0.27%)
6,747.00
(-0.60%)
4,514.10
(+1.28%)
1,433.10
(+1.23%)
1,112.20
(+2.46%)
1,301.30
(+0.82%)
2,357.80
(+0.76%)
2,528.60
(-0.38%)
1,534.20
(+2.84%)
1,481.00
(+3.14%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
